Siemens Forecast, price target & analysts
Siemens Target price 2024 - Analyst rating & recommendation
Siemens Classifications & Recommendation:
Siemens Price Target
| Target Price | €205.57 |
| Price | €193.70 |
| Potential | 6.13% |
| Number of Estimates | 20 |
| 20 Analysts have issued a price target Siemens 2025 . The average Siemens target price is €205.57. This is 6.13% higher than the current stock price. The highest price target is €230.00 18.74% , the lowest is €130.00 32.89% . | |
| A rating was issued by 23 analysts: 18 Analysts recommend Siemens to buy, 4 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Siemens stock has an average upside potential 2025 of 6.13% . Most analysts recommend the Siemens stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2029
19 Analysts have issued a sales forecast Siemens 2025 . The average Siemens sales estimate is €79.4b . This is 2.70% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €81.9b 6.00% , the lowest is €78.3b 1.26% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | €75.9b | 2.36% |
|---|---|---|
| 2025 | €79.4b | 4.54% |
| 2026 | €84.6b | 6.53% |
| 2027 | €90.0b | 6.39% |
| 2028 | €94.9b | 5.50% |
| 2029 | €99.7b | 5.10% |
17 Analysts have issued an Siemens EBITDA forecast 2025. The average Siemens EBITDA estimate is €14.4b . This is 12.12% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €17.3b 34.92% , the lowest is €12.3b 4.14% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | €12.7b | 3.11% |
|---|---|---|
| 2025 | €14.4b | 13.13% |
| 2026 | €16.1b | 11.93% |
| 2027 | €18.2b | 13.26% |
| 2028 | €18.3b | 0.34% |
| 2029 | €19.3b | 5.42% |
EBITDA Margin
| 2024 | 16.75% | 0.76% |
|---|---|---|
| 2025 | 18.13% | 8.22% |
| 2026 | 19.05% | 5.07% |
| 2027 | 20.28% | 6.46% |
| 2028 | 19.29% | 4.88% |
| 2029 | 19.35% | 0.31% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
15 Analysts have issued a Siemens forecast for earnings per share. The average Siemens <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is €11.50 . This is 9.32% higher than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is €12.73 21.01% , the lowest is €9.42 10.46% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | €10.53 | 4.88% |
|---|---|---|
| 2025 | €11.50 | 9.21% |
| 2026 | €11.43 | 0.61% |
| 2027 | €13.11 | 14.70% |
| 2028 | €12.22 | 6.79% |
| 2029 | €13.04 | 6.71% |
P/E ratio
| Current | 18.35 | 18.16% |
|---|---|---|
| 2025 | 16.79 | 8.50% |
| 2026 | 16.88 | 0.54% |
| 2027 | 14.73 | 12.74% |
| 2028 | 15.79 | 7.20% |
| 2029 | 14.81 | 6.21% |
Based on analysts' sales estimates for 2025, the Siemens stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 2.46 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 1.90 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 2.52 | 25.37% |
|---|---|---|
| 2025 | 2.46 | 2.54% |
| 2026 | 2.31 | 6.13% |
| 2027 | 2.17 | 6.01% |
| 2028 | 2.05 | 5.21% |
| 2029 | 1.95 | 4.85% |
P/S ratio
| Current | 1.96 | 31.42% |
|---|---|---|
| 2025 | 1.90 | 2.63% |
| 2026 | 1.79 | 6.13% |
| 2027 | 1.68 | 6.01% |
| 2028 | 1.59 | 5.21% |
| 2029 | 1.52 | 4.85% |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
